D
Kalaris Therapeutics, Inc. KLRS
$8.65 -$0.33-3.68% NASDAQ
Recommendation
Dividend Power Score
Prev Close
$8.98
Volume
27,708
Avg Vol (90D)
138,008
Market Cap
$167.95M
Dividend & Yield
--
52-Week Range
$2.14 - $12.90
P/E (TTM)
--
EPS (TTM)
-$3.76
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
Kalaris Therapeutics (KLRS, $8.98) entered Downtrend as Momentum indicator drops below 0 level on Feb 12, 2026
2/13/2026 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $10.06) Stochastic Oscillator left the oversold zone on February 10, 2026
2/11/2026 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $10.06) entered Uptrend as Momentum indicator ascends above 0 level on Feb 10, 2026
2/11/2026 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $9.13) price moved above its 50-day Moving Average on February 09, 2026
2/10/2026 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $8.33) price exceeded its 50-day Moving Average on February 05, 2026
2/6/2026 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $8.33) Aroon Indicator entered an Uptrend on February 05, 2026.
2/6/2026 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $8.9) Aroon Indicator entered an Uptrend on February 04, 2026.
2/5/2026 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $9.11) Stochastic Oscillator left the oversold zone on February 02, 2026
2/3/2026 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $9.11) entered Downtrend as Momentum indicator drops below 0 level on Feb 02, 2026
2/3/2026 - Tickeron - Stocks
Kalaris Therapeutics (NASDAQ:KLRS) Rating Lowered to "Sell" at Wall Street Zen
2/2/2026 - Ticker Report
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Increases By 60.8%
2/1/2026 - MarketBeat
Kalaris Therapeutics (KLRS, $8.88) Stochastic Oscillator left the oversold zone on January 30, 2026
1/31/2026 - Tickeron - Stocks
Kalaris Therapeutics (NASDAQ:KLRS) Downgraded to "Sell" Rating by Wall Street Zen
1/31/2026 - MarketBeat
Kalaris Therapeutics (KLRS, $9.2) entered Downtrend as Momentum indicator drops below 0 level on Jan 29, 2026
1/30/2026 - Tickeron - Stocks
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
1/28/2026 - Globe Newswire
Kalaris Therapeutics (KLRS, $9.61) Moving Average Convergence Divergence (MACD) Histogram turned negative on January 27, 2026
1/28/2026 - Tickeron - Stocks
Kalaris Therapeutics (NASDAQ:KLRS) Rating Lowered to Sell at Wall Street Zen
1/24/2026 - MarketBeat
Kalaris Therapeutics (KLRS, $9.79) Moving Average Convergence Divergence (MACD) Histogram turned positive on January 21, 2026
1/22/2026 - Tickeron - Stocks
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Consensus Rating of "Moderate Buy" by Brokerages
1/17/2026 - MarketBeat
Kalaris Therapeutics (KLRS, $9.24) entered Uptrend as Momentum indicator ascends above 0 level on Jan 13, 2026
1/14/2026 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $8.84) entered Downtrend as Momentum indicator drops below 0 level on Jan 12, 2026
1/13/2026 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $9.78) Stochastic Oscillator left the oversold zone on January 09, 2026
1/10/2026 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $9.78) entered Uptrend as Momentum indicator ascends above 0 level on Jan 09, 2026
1/10/2026 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $8.38) Stochastic Oscillator left the oversold zone on December 30, 2025
12/31/2025 - Tickeron - Stocks
Kalaris Therapeutics (KLRS, $8.38) Moving Average Convergence Divergence (MACD) Histogram turned negative on December 30, 2025
12/31/2025 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
$81.18M
Total Debt (Q)
$1.55M
Total Liabilities (Q)
$39.31M
Book Value Per Share (Q)
$2.24
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Wednesday, November 12, 2025
Period Date
Tuesday, September 30, 2025
Next Filing
Week of Jan 12 and 16 (est)
Price History
Loading...
Beta
--
7-Day Total Return
-2.04%
30-Day Total Return
2.49%
60-Day Total Return
59.59%
90-Day Total Return
7.72%
Year to Date Total Return
4.22%
1-Year Total Return
--
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Aug 14, 2025 - $2.14
52-week High
Mar 20, 2025 - $12.90
Valuation
Market Cap
$167.95M - Micro Cap
Enterprise Value
$92.49M
Price/Sales (TTM)
--
Price/Book (Q)
4.01
Dividends and Shares
Shares Outstanding
18.70M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
kalaristx.com
Phone Number
Address
628 Middlefield Road
Palo Alto, CA 94301
Country
United States
Year Founded
2019
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was... more
NASDAQ 02/13/2026 4:00PM Eastern Quotes delayed